Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity
Medtronic plc (NSYE: MDT) announced today a new data that shows use of its cardiac resynchronization therapy (CRT) devices – with its proprietary AdaptivCRT(TM) and EffectiveCRT(TM) algorithms – results in lower healthcare system costs, and improves therapy delivery in heart failure patients who also have atrial fibrillation (AF). The results of three analyses were presented at the EHRA EUROPACE-CARDIOSTIM 2017 in Vienna.
Findings from a European health-economic analysis demonstrated that treating patients with AdaptivCRT results in lower healthcare costs and extends life expectancy by an average of four months. The findings, which span three countries’ healthcare systems, showed that lifetime costs for patients treated with AdaptivCRT were lower than for patients treated with traditional pacing algorithms:
|With AdaptivCRT algorithm||Without AdaptivCRT algorithm|
|United Kingdom||€29,425.37 (£25,454.47)||€30,273.19 (£26,274.39)|
The AdaptivCRT algorithm is available in the Medtronic Claria MRI(TM) Quad CRT-D SureScan(TM), Amplia MRI(TM) Quad CRT-D SureScan(TM), Percepta(TM) Quad CRT-P MRI SureScan(TM) and Serena(TM) Quad CRT-P MRI SureScan(TM) systems. It adjusts the way the device paces the heart according to minute-to-minute evaluations of each patient’s rhythm, and leads to improved outcomes through reducing patients’ odds of a 30-day heart failure readmission1 and their risk of developing AF2.
A second analysis – from the prospective, randomized CRTee study – showed that the Medtronic device-based EffectivCRT during AF algorithm improved effective left ventricular pacing by 19 percent (87±16 percent vs. 68 ± 37 percent; p<0.001) in patients with AF, compared to devices without the technology.
Giuseppe Boriani, M.D., Ph.D., full professor of cardiology at the University of Modena and Reggio Emilia, Italy reports, “It is exciting to see that this technology helps increase the amount of CRT delivered during atrial fibrillation.” He went on to say, “Many patients with heart failure experience AF at some point, and we now have the ability to better address the individual needs of these difficult-to-treat patients.”
AF is one of the most common heart rhythm disorders. It involves an irregular quivering or rapid rhythm in the heart’s upper chambers. A large percentage of heart failure patients receiving CRT also have AF3, which can significantly reduce patient response to the therapy. The EffectivCRT Diagnostic, exclusive to the Medtronic Claria CRT-D and Percepta CRT-P devices, automatically determines the effectiveness of left ventricular pacing, and the EffectivCRT during AF algorithm automatically adjusts pacing rates during AF.
Vice President and general manager of the CRT business, (part of the Cardiac and Vascular Group at Medtronic), Kweli P. Thompson, M.D., M.P.H. added, “These analyses reinforce Medtronic’s leadership in providing treatments and solutions that not only improve patient outcomes and CRT delivery, but also dramatically reduce healthcare utilization.” “Beyond the clinical benefits of the AdaptivCRT and EffectivCRT algorithms, our newest devices with these features also demonstrate improved longevity,” concluded Thompson.
Finally, the latest economic analysis of Medtronic CRT-defibrillators (CRT-D) demonstrated a highly significant increase in projected device longevity: up to nine (9) years for Claria and Amplia devices, and 8.1 years in Viva XT(TM) CRT-Ds, which are substantial improvements compared to predecessor models.
“By improving device longevity, there are substantially fewer device replacements and, in turn, significant cost savings and fewer procedure-related complications,” said Haran Burri, M.D., Ph.D., associate professor of cardiology at the University Hospital of Geneva, Switzerland.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.